v3.26.1
Collaboration, License, and Other Agreements - Sanofi, Antibody Narrative (Details) - Sanofi Collaboration Agreement, Antibody
$ in Millions
3 Months Ended
Mar. 31, 2026
USD ($)
Disaggregation of Revenue [Line Items]  
Percentage share of profits to reimburse collaborating party 20.00%
Contingent reimbursement obligation $ 278
Starting share of profits outside the United States, based on sales, for collaborating party 65.00%
Starting share of profits outside the United States, based on sales, for Company 35.00%
Ending share of profits outside the United States, based on sales, for collaborating party 55.00%
Ending share of profits outside the United States, based on sales, for Company 45.00%
Minimum  
Disaggregation of Revenue [Line Items]  
Percentage of trial costs required to be funded by collaborating party 80.00%
Percentage share of profits to reimburse collaborating party 30.00%
Maximum  
Disaggregation of Revenue [Line Items]  
Percentage of trial costs required to be funded by collaborating party 100.00%
Percentage share of profits to reimburse collaborating party 50.00%